| アブストラクト | OBJECTIVE: To create case definitions for confirmed COVID-19 diagnoses, COVID-19 vaccination status and three separate definitions of high risk of severe COVID-19, as well as to assess whether the implementation of these definitions in a cohort reflected the sociodemographic and clinical characteristics of COVID-19 epidemiology in England. DESIGN: Retrospective cohort study. SETTING: Electronic healthcare records from primary care (Clinical Practice Research Datalink, CPRD) linked to secondary care data (Hospital Episode Statistics) data covering 24% of the population in England. PARTICIPANTS: 2 271 072 persons aged 1 year and older diagnosed with COVID-19 in CPRD Aurum between 1 August 2020 and 31 January 2022. MAIN OUTCOME MEASURES: Age, sex and regional distribution of COVID-19 cases and COVID-19 vaccine doses received prior to diagnosis were assessed separately for the cohorts of cases identified in primary care and those hospitalised for COVID-19 (primary diagnosis code of ICD-10 U07.1 'COVID-19'). Smoking status, body mass index and Charlson Comorbidity Index were compared for the two cohorts, as well as for three separate definitions of high risk of severe disease used in the UK (National Health Service Highest Risk, PANORAMIC trial eligibility, UK Health Security Agency Clinical Risk prioritisation for vaccination). RESULTS: Compared with national estimates, CPRD case estimates under-represented older adults in both the primary care (age 65-84: 6% in CPRD vs 9% nationally) and hospitalised (31% vs 40%) cohorts, and over-represented people living in regions with the highest median wealth areas of England (20% primary care and 20% hospital admitted cases in South East vs 15% nationally). The majority of non-hospitalised cases and all hospitalised cases had not completed primary series vaccination. In primary care, persons meeting high-risk definitions were older, more often smokers, overweight or obese, and had higher Charlson Comorbidity Index score. CONCLUSIONS: CPRD primary care data are a robust real-world data source and can be used for some COVID-19 research questions, however, limitations of the data availability should be carefully considered. Included in this publication are supplemental files for a total of over 28 000 codes to define each of three definitions of high risk of severe disease. |
|---|
| ジャーナル名 | BMJ open |
|---|
| Pubmed追加日 | 2024/1/13 |
|---|
| 投稿者 | Andersen, Kathleen M; McGrath, Leah J; Reimbaeva, Maya; Mendes, Diana; Nguyen, Jennifer L; Rai, Kiran K; Tritton, Theo; Tsang, Carmen; Malhotra, Deepa; Yang, Jingyan |
|---|
| 組織名 | Pfizer Inc, New York, New York, USA kathleen.andersen@pfizer.com.;Pfizer Inc, New York, New York, USA.;Pfizer Ltd, Tadworth, UK.;Adelphi Real World, Bollington, UK.;Institute for Social and Economic Research and Policy, Columbia University, New;York, New York, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38216179/ |
|---|
